{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:16Z","timestamp":1786982776672,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:00:00Z","timestamp":1536364800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["10\/354"],"award-info":[{"award-number":["10\/354"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40266-018-0582-y","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T22:30:35Z","timestamp":1536359435000},"page":"1005-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medication Exposure and Health Outcomes in Older Patients with End-Stage Kidney Disease: A Prospective Study Undertaken in New Zealand"],"prefix":"10.1007","volume":"35","author":[{"given":"Sashika","family":"Samaranayaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3366-0956","authenticated-orcid":false,"given":"Robert J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Samaranayaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Derrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W. B.","family":"Schollum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,8]]},"reference":[{"issue":"5","key":"582_CR1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/diacare.26.5.1408","volume":"26","author":"RW Grant","year":"2003","unstructured":"Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408\u201312.","journal-title":"Diabetes Care"},{"key":"582_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ams2.153","volume":"3","author":"T Abe","year":"2016","unstructured":"Abe T, Tamiya N, Kitahara T, Tokuda Y. Polypharmacy as a risk factor for hospital admission among ambulance-transported old-old patients. Acute Med Surg. 2016;3:107\u201313.","journal-title":"Acute Med Surg."},{"issue":"7","key":"582_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2165\/11592000-000000000-00000","volume":"28","author":"K Richardson","year":"2011","unstructured":"Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547\u201360.","journal-title":"Drugs Aging"},{"issue":"1","key":"582_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2369-13-96","volume":"13","author":"Y-P Chang","year":"2012","unstructured":"Chang Y-P, Huang S-K, Tao P, Chien C-W. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrol. 2012;13(1):96.","journal-title":"BMC Nephrol."},{"issue":"2","key":"582_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.healthpol.2012.09.005","volume":"109","author":"B Hovstadius","year":"2013","unstructured":"Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure\u2014a register-based study in Sweden 2005\u20132009. Health Policy. 2013;109(2):166\u201374.","journal-title":"Health Policy"},{"issue":"4","key":"582_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1041-2972.2005.0020.x","volume":"17","author":"MM Fulton","year":"2005","unstructured":"Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123\u201332.","journal-title":"J Am Acad Nurse Pract."},{"issue":"1","key":"582_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/ggi.12059","volume":"14","author":"PS Nishtala","year":"2014","unstructured":"Nishtala PS, Bagge ML, Campbell AJ, Tordoff JM. Potentially inappropriate medicines in a cohort of community-dwelling older people in New Zealand. Geriatr Gerontol Int. 2014;14(1):89\u201393.","journal-title":"Geriatr Gerontol Int."},{"issue":"3","key":"582_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000368191","volume":"61","author":"PS Nishtala","year":"2014","unstructured":"Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005\u20132013. Gerontol. 2014;61(3):195\u2013202.","journal-title":"Gerontol."},{"key":"582_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1053\/j.ajkd.2017.02.374","volume":"70","author":"C McIntyre","year":"2017","unstructured":"McIntyre C, McQuillan R, Bell C, Battistella M. Targeted deprescribing in an outpatient hemodialysis unit: a quality improvement study to decrease polypharmacy. Am J Kidney Dis. 2017;70:611\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"582_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cger.2012.01.001","volume":"28","author":"B Hovstadius","year":"2012","unstructured":"Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatric Med. 2012;28(2):159\u201372.","journal-title":"Clin Geriatric Med."},{"key":"582_CR11","doi-asserted-by":"crossref","unstructured":"Mason NA, Bakus JL, editors. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial. 2010;23:55\u201361.","DOI":"10.1111\/j.1525-139X.2009.00629.x"},{"issue":"10","key":"582_CR12","doi-asserted-by":"publisher","first-page":"M554","DOI":"10.1093\/gerona\/55.10.M554","volume":"55","author":"JH Flaherty","year":"2000","unstructured":"Flaherty JH, Perry HM, Lynchard GS, Morley JE. Polypharmacy and hospitalisation among older home care patients. J Gerontol A Biol Sci Med Sci. 2000;55(10):M554\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"582_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ggi.12241","volume":"15","author":"F Sganga","year":"2015","unstructured":"Sganga F, Landi F, Ruggiero C, et al. Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study. Geriatr Gerontol Int. 2015;15(2):141\u20136.","journal-title":"Geriatr Gerontol Int."},{"issue":"2","key":"582_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/gerona\/61.2.170","volume":"61","author":"DV Espino","year":"2006","unstructured":"Espino DV, Bazaldua OV, Palmer RF, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE study. J Gerontol A Biol Sci Med Sci. 2006;61(2):170\u20135.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"582_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2165\/11319530-000000000-00000","volume":"26","author":"J Jyrkk\u00e4","year":"2009","unstructured":"Jyrkk\u00e4 J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039\u201348.","journal-title":"Drugs Aging"},{"issue":"89","key":"582_CR16","first-page":"247","volume":"2013","author":"SA Jones","year":"1051","unstructured":"Jones SA, Bhandari S. The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgrad Med J. 1051;2013(89):247\u201350.","journal-title":"Postgrad Med J"},{"issue":"4","key":"582_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/sdi.12377","volume":"28","author":"WL St Peter","year":"2015","unstructured":"St Peter WL. Management of polypharmacy in dialysis patients. Semin Dial. 2015;28(4):427\u201332.","journal-title":"Semin Dial"},{"issue":"4","key":"582_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1053\/j.ajkd.2005.07.001","volume":"46","author":"HJ Manley","year":"2005","unstructured":"Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669\u201380.","journal-title":"Am J Kidney Dis"},{"key":"582_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1471-2369-14-175","volume":"14","author":"R Walker","year":"2013","unstructured":"Walker R, Derrett S, Campbell J, et al. Dialysis outcomes in those aged\u2009\u2265\u200965 years. BMC Nephrol. 2013;14:175.","journal-title":"BMC Nephrol."},{"key":"582_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0272-6386(04)01099-6","volume":"44","author":"RL Pisoni","year":"2004","unstructured":"Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004;44:7\u201315.","journal-title":"Am J Kidney Dis"},{"key":"582_CR21","volume-title":"HISO 10001:2017 ethnicity data protocols","author":"Ministry of Health","year":"2017","unstructured":"Ministry of Health. HISO 10001:2017 ethnicity data protocols. Wellington: Ministry of Health; 2017."},{"key":"582_CR22","unstructured":"World Health Organization. Global database on body mass index. \n                    http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html\n                    \n                  . Accessed 20 Dec 2017."},{"key":"582_CR23","volume-title":"EQ-5D-3L user guide","author":"MV Reenen","year":"2015","unstructured":"Reenen MV, Oppe M. EQ-5D-3L user guide. Rotterdam: EuroQol Research Foundation; 2015."},{"issue":"7","key":"582_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136.","journal-title":"Am J Epidemiol"},{"key":"582_CR25","unstructured":"Statistics New Zealand. Ethnic group (total responses) by age group and sex, for the census usually resident population count, 2001, 2006, and 2013 Censuses. Wellington: Statistics New Zealand; 2013. \n                    https:\/\/www.stats.govt.nz\/topics\/census\n                    \n                  . Accessed 24 Aug 2018."},{"key":"582_CR26","volume-title":"ANZDATA Registry report 2010: the Australia and New Zealand Dialysis and Transplant Registry","year":"2010","unstructured":"McDonald S, Excell L, Livingston B, editors. ANZDATA Registry report 2010: the Australia and New Zealand Dialysis and Transplant Registry. ANZDATA registry: Adelaide; 2010."},{"issue":"3","key":"582_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/bcp.12975","volume":"82","author":"AT Page","year":"2016","unstructured":"Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583\u2013623.","journal-title":"Br J Clin Pharmacol"},{"key":"582_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0272-6386(04)01107-2","volume":"44","author":"VE Andreucci","year":"2004","unstructured":"Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44:61\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"582_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","volume":"62","author":"B Iorio Di","year":"2013","unstructured":"Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, INDEPENDENT Study Investigators, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771\u20138.","journal-title":"Am J Kidney Dis"},{"key":"582_CR30","doi-asserted-by":"crossref","unstructured":"Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;5(5):CD008165.","DOI":"10.1002\/14651858.CD008165.pub2"},{"issue":"6","key":"582_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/clpt.2011.44","volume":"89","author":"P Gallagher","year":"2011","unstructured":"Gallagher P, O\u2019Connor M, O\u2019Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP\/START criteria. Clin Pharmacol Ther. 2011;89(6):845\u201354.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"582_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/eb-2012-100930","volume":"18","author":"IA Scott","year":"2013","unstructured":"Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med. 2013;18(4):121\u20134.","journal-title":"Evid Based Med."},{"issue":"1","key":"582_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11096-013-9871-z","volume":"36","author":"E Reeve","year":"2014","unstructured":"Reeve E, Wiese MD. Benefits of deprescribing on patients\u2019 adherence to medications. Int J Clin Pharm. 2014;36(1):26\u20139.","journal-title":"Int J Clin Pharm."},{"issue":"4","key":"582_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease. A systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263\u201375.","journal-title":"Ann Intern Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0582-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T05:47:56Z","timestamp":1569044876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0582-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,8]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0582-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,8]]},"assertion":[{"value":"8 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The DOS65\u2009+\u2009(Dialysis Outcomes in those aged\u2009\u2265\u200965 years Study) was funded by the Health Research Council (HRC) of New Zealand (HRC 10\/354). The study was investigator-initiated and analysed, with no contribution from the HRC to the analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sashika Samaranayaka, Robert Walker, Ari Samaranayaka, Sarah Derrett and John Schollum declare that they have no conflicts of interest relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the New Zealand Multi-Regional Ethics Committee (MEC\/10\/084) and registered in Australian New Zealand clinical trials registry (ACTRN12611000024943).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}